RxSight (RXST) Financials

$7.26 -0.12 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$7.27 +0.01 (+0.14%)

As of 04:56 PM Eastern

Annual Income Statements for RxSight

This table shows RxSight's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-67	-49	-27
Consolidated Net Income / (Loss)	-67	-49	-27
Net Income / (Loss) Continuing Operations	-67	-49	-27
Total Pre-Tax Income	-67	-49	-27
Total Operating Income	-63	-50	-37
Total Gross Profit	21	54	99
Total Revenue	49	89	140
Operating Revenue	49	89	140
Total Cost of Revenue	28	35	41
Operating Cost of Revenue	28	35	41
Total Operating Expenses	85	104	136
Selling, General & Admin Expense	59	75	101
Research & Development Expense	26	29	34
Total Other Income / (Expense), net	-3.43	1.50	9.45
Interest Expense	4.95	5.08	0.02
Interest & Investment Income	1.52	6.57	9.47
Income Tax Expense	0.01	0.02	0.05
Basic Earnings per Share	($2.41)	($1.41)	($0.71)
Weighted Average Basic Shares Outstanding	27.66M	34.46M	38.87M
Diluted Earnings per Share	($2.41)	($1.41)	($0.71)
Weighted Average Diluted Shares Outstanding	27.66M	34.46M	38.87M
Weighted Average Basic & Diluted Shares Outstanding	33.78M	36.99M	40.49M

This table shows RxSight's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-17	-16	-13	-14	-12	-9.18	-9.10	-6.08	-6.34	-5.94
Consolidated Net Income / (Loss)	-17	-16	-13	-14	-12	-9.18	-9.10	-6.08	-6.34	-5.94
Net Income / (Loss) Continuing Operations	-17	-16	-13	-14	-12	-9.18	-9.10	-6.08	-6.34	-5.94
Total Pre-Tax Income	-17	-16	-13	-14	-12	-9.20	-9.09	-6.06	-6.33	-5.93
Total Operating Income	-16	-15	-13	-14	-13	-11	-11	-8.33	-9.23	-8.63
Total Gross Profit	5.36	7.42	10	12	14	18	21	24	25	29
Total Revenue	13	16	17	21	22	29	30	35	35	40
Operating Revenue	13	16	17	21	22	29	30	35	35	40
Total Cost of Revenue	7.26	8.67	7.12	8.80	8.47	11	8.83	11	10	11
Operating Cost of Revenue	7.26	8.67	7.12	8.80	8.47	11	8.83	11	10	11
Total Operating Expenses	21	22	23	26	26	29	31	33	34	37
Selling, General & Admin Expense	15	16	16	18	19	21	23	24	26	28
Research & Development Expense	6.39	6.68	7.21	7.40	7.10	7.34	8.03	8.29	8.84	9.21
Total Other Income / (Expense), net	-0.86	-0.62	-0.12	-0.15	0.11	1.66	1.58	2.27	2.90	2.70
Interest Expense	1.30	1.45	1.51	1.93	1.64	0.00	0.01	0.01	0.01	0.00
Interest & Investment Income	0.44	0.84	1.39	1.78	1.75	1.66	1.59	2.28	2.91	2.71
Income Tax Expense	0.00	0.01	0.00	0.03	0.01	-0.02	0.01	0.02	0.01	0.01
Basic Earnings per Share	($0.61)	($0.55)	($0.42)	($0.40)	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)
Weighted Average Basic Shares Outstanding	27.67M	27.66M	31.64M	34.50M	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M
Diluted Earnings per Share	($0.61)	($0.55)	($0.42)	($0.40)	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)
Weighted Average Diluted Shares Outstanding	27.67M	27.66M	31.64M	34.50M	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M
Weighted Average Basic & Diluted Shares Outstanding	27.72M	33.78M	33.98M	35.64M	35.86M	36.99M	37.20M	39.68M	40.30M	40.49M

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-13	-2.19	7.05
Net Cash From Operating Activities	-59	-42	-17
Net Cash From Continuing Operating Activities	-59	-42	-17
Net Income / (Loss) Continuing Operations	-67	-49	-27
Consolidated Net Income / (Loss)	-67	-49	-27
Depreciation Expense	3.88	4.08	3.58
Amortization Expense	-0.72	-5.67	-8.93
Non-Cash Adjustments To Reconcile Net Income	12	18	25
Changes in Operating Assets and Liabilities, net	-7.41	-9.07	-9.21
Net Cash From Investing Activities	40	-22	-99
Net Cash From Continuing Investing Activities	40	-22	-99
Purchase of Property, Plant & Equipment	-2.39	-4.81	-5.44
Purchase of Investments	-213	-272	-337
Sale and/or Maturity of Investments	255	255	243
Net Cash From Financing Activities	6.33	62	123
Net Cash From Continuing Financing Activities	6.33	62	123
Repayment of Debt	-0.15	-62	0.00
Repurchase of Common Equity	-0.59	-0.62	-0.77
Issuance of Debt	0.00	20	0.00
Issuance of Common Equity	7.83	106	129
Other Financing Activities, net	-0.76	-1.58	-4.83
Effect of Exchange Rate Changes	-0.01	0.01	-0.01
Cash Interest Paid	4.26	3.48	0.02
Cash Income Taxes Paid	0.00	0.01	0.02

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-15	2.87	-0.82	-2.26	1.06	-0.17	23	-8.20	-7.73	0.02
Net Cash From Operating Activities	-15	-14	-18	-7.55	-7.98	-8.30	-9.31	-4.03	0.65	-4.26
Net Cash From Continuing Operating Activities	-15	-14	-18	-7.55	-7.98	-8.30	-9.31	-4.03	0.65	-4.29
Net Income / (Loss) Continuing Operations	-17	-16	-13	-14	-12	-9.18	-9.10	-6.08	-6.34	-5.94
Consolidated Net Income / (Loss)	-17	-16	-13	-14	-12	-9.18	-9.10	-6.08	-6.34	-5.94
Depreciation Expense	0.94	0.92	0.96	0.99	1.08	1.05	1.12	0.81	1.13	0.52
Amortization Expense	-0.21	-0.60	-1.07	-1.51	-1.54	-1.54	-1.48	-2.07	-2.76	-2.62
Non-Cash Adjustments To Reconcile Net Income	3.22	3.23	3.31	4.32	5.48	4.58	4.81	6.16	6.75	7.32
Changes in Operating Assets and Liabilities, net	-2.32	-1.83	-7.74	2.46	-0.59	-3.21	-4.65	-2.86	1.87	-3.57
Net Cash From Investing Activities	0.56	10	-48	4.40	17	4.57	24	-116	-9.26	1.32
Net Cash From Continuing Investing Activities	0.56	10	-48	4.40	17	4.57	24	-116	-9.26	1.32
Purchase of Property, Plant & Equipment	-0.58	-0.36	-0.75	-1.82	-0.65	-1.59	-1.97	-1.52	-1.10	-0.85
Purchase of Investments	-74	-34	-108	-49	-72	-44	-48	-159	-77	-53
Sale and/or Maturity of Investments	75	45	60	55	90	50	74	45	69	55
Net Cash From Financing Activities	-0.46	6.31	65	0.89	-8.23	3.56	7.99	111	0.88	2.98
Net Cash From Continuing Financing Activities	-0.46	6.31	65	0.89	-8.23	3.56	7.99	111	0.88	2.98
Issuance of Common Equity	0.15	6.64	66	23	14	3.58	10	112	3.84	2.99
Other Financing Activities, net	-0.30	-0.04	-0.38	-0.04	-1.12	-0.04	-2.16	-0.01	-2.65	-0.01
Effect of Exchange Rate Changes	-0.01	0.01	0.00	0.00	-0.01	0.01	-0.00	-0.00	0.01	-0.01
Cash Interest Paid	1.13	1.22	1.35	1.90	0.23	0.00	0.01	0.01	0.01	0.01
Cash Income Taxes Paid	-	-	0.00	0.01	-	-0.00	0.00	0.02	0.00	-0.00

This table presents RxSight's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	150	183	319
Total Current Assets	135	168	294
Cash & Equivalents	12	9.69	17
Short-Term Investments	94	117	221
Accounts Receivable	11	20	30
Inventories, net	15	17	22
Prepaid Expenses	2.96	3.52	4.54
Plant, Property, & Equipment, net	10	11	12
Total Noncurrent Assets	5.47	3.30	12
Other Noncurrent Operating Assets	5.47	3.30	12
Total Liabilities & Shareholders' Equity	150	183	319
Total Liabilities	60	22	37
Total Current Liabilities	17	21	26
Accounts Payable	2.60	3.86	4.54
Accrued Expenses	13	15	20
Other Current Liabilities	1.97	1.80	0.97
Total Noncurrent Liabilities	43	1.29	11
Long-Term Debt	40	0.07	0.13
Capital Lease Obligations	2.86	1.21	11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	90	160	281
Total Preferred & Common Equity	90	160	281
Preferred Stock	0.00	0.00	0.00
Total Common Equity	90	160	281
Common Stock	636	755	903
Retained Earnings	-546	-595	-622
Accumulated Other Comprehensive Income / (Loss)	-0.10	-0.01	0.17

This table presents RxSight's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	156	203	195	182	183	305	310
Total Current Assets	139	188	180	168	169	281	287
Cash & Equivalents	8.91	11	8.75	9.86	33	24	17
Short-Term Investments	104	143	138	122	93	209	220
Accounts Receivable	9.02	13	13	15	22	26	25
Inventories, net	15	18	18	19	19	19	22
Prepaid Expenses	1.97	2.99	2.11	1.90	2.96	2.77	2.61
Plant, Property, & Equipment, net	11	9.80	11	10	12	12	12
Total Noncurrent Assets	5.92	5.06	4.28	3.64	2.99	12	11
Other Noncurrent Operating Assets	5.92	5.06	4.28	3.64	2.99	12	11
Total Liabilities & Shareholders' Equity	156	203	195	182	183	305	310
Total Liabilities	60	58	38	20	19	30	33
Total Current Liabilities	16	15	17	19	18	20	23
Accounts Payable	4.17	3.72	4.00	4.11	5.06	5.10	4.58
Accrued Expenses	10	9.18	11	13	12	14	17
Other Current Liabilities	1.95	1.98	1.98	1.98	1.61	0.74	0.73
Total Noncurrent Liabilities	43	43	22	1.43	0.91	11	11
Long-Term Debt	40	40	20	0.08	0.00	0.00	0.00
Capital Lease Obligations	3.35	2.34	1.84	1.35	0.91	11	11
Other Noncurrent Operating Liabilities	-	-	-	0.00	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	96	145	157	161	164	275	277
Total Preferred & Common Equity	96	145	157	161	164	275	277
Preferred Stock	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Common Equity	96	145	157	161	164	275	277
Common Stock	627	704	730	747	768	885	893
Retained Earnings	-530	-559	-573	-585	-604	-610	-616
Accumulated Other Comprehensive Income / (Loss)	-0.14	-0.01	-0.07	-0.06	-0.05	-0.12	0.52

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	116.90%	81.77%	57.09%
EBITDA Growth	-17.82%	14.09%	18.32%
EBIT Growth	-14.08%	20.90%	26.41%
NOPAT Growth	-19.95%	20.90%	26.41%
Net Income Growth	-37.11%	27.19%	43.52%
EPS Growth	32.49%	41.49%	49.65%
Operating Cash Flow Growth	-31.63%	29.32%	59.26%
Free Cash Flow Firm Growth	-14.30%	13.71%	-10.38%
Invested Capital Growth	21.57%	27.06%	60.93%
Revenue Q/Q Growth	18.53%	16.31%	9.07%
EBITDA Q/Q Growth	13.40%	6.04%	1.42%
EBIT Q/Q Growth	13.79%	7.63%	5.69%
NOPAT Q/Q Growth	-0.52%	7.63%	5.69%
Net Income Q/Q Growth	0.18%	11.69%	10.55%
EPS Q/Q Growth	-97.54%	18.02%	12.35%
Operating Cash Flow Q/Q Growth	-9.55%	11.78%	19.25%
Free Cash Flow Firm Q/Q Growth	0.00%	0.19%	0.51%
Invested Capital Q/Q Growth	2.35%	11.08%	9.37%
Profitability Metrics	-	-	-
Gross Margin	43.52%	60.36%	70.71%
EBITDA Margin	-122.74%	-58.01%	-30.17%
Operating Margin	-129.21%	-56.23%	-26.34%
EBIT Margin	-129.21%	-56.23%	-26.34%
Profit (Net Income) Margin	-136.22%	-54.57%	-19.62%
Tax Burden Percent	100.01%	100.04%	100.18%
Interest Burden Percent	105.42%	97.01%	74.35%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-179.31%	-113.85%	-57.38%
ROIC Less NNEP Spread (ROIC-NNEP)	-154.20%	-99.49%	-56.44%
Return on Net Nonoperating Assets (RNNOA)	120.79%	75.00%	44.95%
Return on Equity (ROE)	-58.52%	-38.85%	-12.43%
Cash Return on Invested Capital (CROIC)	-198.78%	-137.68%	-104.08%
Operating Return on Assets (OROA)	-36.93%	-30.11%	-14.71%
Return on Assets (ROA)	-38.94%	-29.22%	-10.96%
Return on Common Equity (ROCE)	-58.52%	-38.85%	-12.43%
Return on Equity Simple (ROE_SIMPLE)	-74.25%	-30.31%	-9.76%
Net Operating Profit after Tax (NOPAT)	-44	-35	-26
NOPAT Margin	-90.45%	-39.36%	-18.44%
Net Nonoperating Expense Percent (NNEP)	-25.11%	-14.36%	-0.94%
Return On Investment Capital (ROIC_SIMPLE)	-33.34%	-21.69%	-8.82%
Cost of Revenue to Revenue	56.48%	39.64%	29.29%
SG&A Expenses to Revenue	119.71%	83.97%	72.49%
R&D to Revenue	53.02%	32.61%	24.56%
Operating Expenses to Revenue	172.73%	116.58%	97.05%
Earnings before Interest and Taxes (EBIT)	-63	-50	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-52	-42
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.91	9.02	4.93
Price to Tangible Book Value (P/TBV)	3.91	9.02	4.93
Price to Revenue (P/Rev)	7.17	16.23	9.90
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	10.63	38.30	20.91
Enterprise Value to Revenue (EV/Rev)	5.89	14.82	8.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.48	0.01	0.04
Long-Term Debt to Equity	0.48	0.01	0.04
Financial Leverage	-0.78	-0.75	-0.80
Leverage Ratio	1.50	1.33	1.13
Compound Leverage Factor	1.58	1.29	0.84
Debt to Total Capital	32.37%	0.79%	3.91%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	32.37%	0.79%	3.91%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	67.63%	99.21%	96.09%
Debt to EBITDA	-0.72	-0.02	-0.27
Net Debt to EBITDA	1.04	2.44	5.35
Long-Term Debt to EBITDA	-0.72	-0.02	-0.27
Debt to NOPAT	-0.97	-0.04	-0.44
Net Debt to NOPAT	1.42	3.59	8.75
Long-Term Debt to NOPAT	-0.97	-0.04	-0.44
Altman Z-Score	-1.72	35.09	20.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.81	8.06	11.36
Quick Ratio	6.77	7.05	10.33
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-49	-42	-47
Operating Cash Flow to CapEx	-2,459.26%	-864.00%	-311.51%
Free Cash Flow to Firm to Interest Expense	-9.93	-8.35	-2,228.55
Operating Cash Flow to Interest Expense	-11.90	-8.19	-806.95
Operating Cash Flow Less CapEx to Interest Expense	-12.38	-9.14	-1,066.00
Efficiency Ratios	-	-	-
Asset Turnover	0.29	0.54	0.56
Accounts Receivable Turnover	6.20	5.70	5.56
Inventory Turnover	2.42	2.19	2.08
Fixed Asset Turnover	4.59	8.49	12.03
Accounts Payable Turnover	12.92	10.94	9.75
Days Sales Outstanding (DSO)	58.91	64.00	65.64
Days Inventory Outstanding (DIO)	150.78	166.71	175.58
Days Payable Outstanding (DPO)	28.25	33.38	37.44
Cash Conversion Cycle (CCC)	181.44	197.33	203.79
Capital & Investment Metrics	-	-	-
Invested Capital	27	34	55
Invested Capital Turnover	1.98	2.89	3.11
Increase / (Decrease) in Invested Capital	4.81	7.34	21
Enterprise Value (EV)	288	1,320	1,160
Market Capitalization	351	1,446	1,386
Book Value per Share	$3.24	$4.47	$6.98
Tangible Book Value per Share	$3.24	$4.47	$6.98
Total Capital	133	162	293
Total Debt	43	1.29	11
Total Long-Term Debt	43	1.29	11
Net Debt	-63	-126	-226
Capital Expenditures (CapEx)	2.39	4.81	5.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	20	31
Debt-free Net Working Capital (DFNWC)	117	148	268
Net Working Capital (NWC)	117	148	268
Net Nonoperating Expense (NNE)	22	14	1.65
Net Nonoperating Obligations (NNO)	-63	-126	-226
Total Depreciation and Amortization (D&A)	3.17	-1.59	-5.35
Debt-free, Cash-free Net Working Capital to Revenue	23.50%	22.81%	21.96%
Debt-free Net Working Capital to Revenue	239.40%	165.59%	191.49%
Net Working Capital to Revenue	239.40%	165.59%	191.49%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.41)	($1.41)	($0.71)
Adjusted Weighted Average Basic Shares Outstanding	27.66M	34.46M	38.87M
Adjusted Diluted Earnings per Share	($2.41)	($1.41)	($0.71)
Adjusted Weighted Average Diluted Shares Outstanding	27.66M	34.46M	38.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.78M	36.99M	40.49M
Normalized Net Operating Profit after Tax (NOPAT)	-44	-35	-26
Normalized NOPAT Margin	-90.45%	-39.36%	-18.44%
Pre Tax Income Margin	-136.20%	-54.55%	-19.59%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-12.80	-9.87	-1,755.14
NOPAT to Interest Expense	-8.96	-6.91	-1,228.60
EBIT Less CapEx to Interest Expense	-13.29	-10.81	-2,014.19
NOPAT Less CapEx to Interest Expense	-9.45	-7.85	-1,487.65
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.88%	-1.28%	-2.80%

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	118.03%	90.93%	95.58%	83.19%	75.97%	77.64%	68.75%	67.65%	59.08%	40.71%
EBITDA Growth	-45.41%	38.82%	14.53%	4.37%	14.82%	22.66%	16.49%	32.25%	16.30%	5.38%
EBIT Growth	-37.46%	40.31%	21.00%	13.72%	21.59%	27.61%	18.53%	38.84%	26.26%	20.48%
NOPAT Growth	-21.71%	-2.23%	21.00%	13.72%	21.59%	27.61%	18.53%	38.84%	26.26%	20.48%
Net Income Growth	-32.71%	0.78%	24.91%	17.50%	26.18%	41.21%	31.12%	55.96%	48.95%	35.29%
EPS Growth	10.29%	-185.94%	34.38%	34.43%	42.62%	56.36%	40.48%	60.00%	54.29%	41.67%
Operating Cash Flow Growth	-10.42%	-58.84%	-18.55%	49.09%	47.45%	40.08%	47.60%	46.63%	108.14%	48.68%
Free Cash Flow Firm Growth	67.93%	0.00%	40.49%	-13.80%	-16.74%	2.42%	34.90%	-67.23%	-96.84%	-81.04%
Invested Capital Growth	0.78%	21.57%	49.48%	25.92%	17.07%	27.06%	17.10%	66.43%	63.45%	60.93%
Revenue Q/Q Growth	11.05%	27.53%	8.71%	18.99%	6.67%	28.74%	3.26%	18.21%	1.22%	13.88%
EBITDA Q/Q Growth	-2.91%	3.66%	9.91%	-7.08%	8.33%	12.54%	2.72%	13.13%	-13.25%	1.12%
EBIT Q/Q Growth	-1.05%	6.07%	12.63%	-4.03%	8.17%	13.28%	1.67%	21.90%	-10.72%	6.47%
NOPAT Q/Q Growth	-1.05%	6.07%	12.63%	-4.03%	8.17%	13.28%	1.67%	21.90%	-10.72%	6.47%
Net Income Q/Q Growth	-0.51%	7.18%	15.36%	-4.48%	10.06%	26.08%	0.84%	33.20%	-4.26%	6.31%
EPS Q/Q Growth	0.00%	9.84%	23.64%	4.76%	12.50%	31.43%	-4.17%	36.00%	0.00%	12.50%
Operating Cash Flow Q/Q Growth	-2.46%	8.78%	-28.22%	57.52%	-5.78%	-4.00%	-12.14%	56.74%	116.14%	-755.38%
Free Cash Flow Firm Q/Q Growth	19.30%	-34.54%	-32.82%	21.09%	17.21%	-12.46%	11.39%	-102.70%	2.55%	-3.43%
Invested Capital Q/Q Growth	5.60%	2.35%	24.30%	-6.27%	-1.83%	11.08%	14.56%	33.21%	-3.59%	9.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	42.46%	46.14%	59.27%	57.74%	61.85%	61.77%	70.09%	69.51%	71.42%	71.59%
EBITDA Margin	-120.70%	-91.17%	-75.56%	-67.99%	-58.43%	-39.69%	-37.39%	-27.48%	-30.74%	-26.69%
Operating Margin	-126.50%	-93.18%	-74.89%	-65.47%	-56.36%	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%
EBIT Margin	-126.50%	-93.18%	-74.89%	-65.47%	-56.36%	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%
Profit (Net Income) Margin	-133.32%	-97.03%	-75.54%	-66.33%	-55.93%	-32.11%	-30.83%	-17.42%	-17.95%	-14.77%
Tax Burden Percent	100.00%	100.03%	100.00%	100.19%	100.10%	99.80%	100.10%	100.26%	100.21%	100.20%
Interest Burden Percent	105.39%	104.10%	100.88%	101.12%	99.13%	84.74%	85.20%	72.76%	68.56%	68.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-138.67%	-129.31%	-107.22%	-108.32%	-105.05%	-76.88%	-69.91%	-45.74%	-57.41%	-46.74%
ROIC Less NNEP Spread (ROIC-NNEP)	-132.85%	-123.58%	-103.41%	-104.26%	-101.39%	-75.20%	-68.53%	-45.60%	-57.48%	-46.80%
Return on Net Nonoperating Assets (RNNOA)	104.43%	96.80%	81.71%	82.13%	78.73%	56.70%	52.29%	36.72%	46.77%	37.27%
Return on Equity (ROE)	-34.24%	-32.51%	-25.52%	-26.18%	-26.32%	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%
Cash Return on Invested Capital (CROIC)	0.00%	-198.78%	-188.53%	-165.34%	-147.68%	-137.68%	-106.90%	-120.31%	-115.10%	-104.08%
Operating Return on Assets (OROA)	-29.10%	-26.63%	-22.71%	-24.24%	-25.58%	-20.33%	-18.95%	-10.99%	-13.62%	-11.98%
Return on Assets (ROA)	-30.67%	-27.73%	-22.91%	-24.56%	-25.38%	-17.19%	-16.17%	-8.02%	-9.35%	-8.25%
Return on Common Equity (ROCE)	-34.24%	-32.51%	-25.52%	-26.18%	-26.32%	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%
Return on Equity Simple (ROE_SIMPLE)	-69.70%	0.00%	-43.01%	-37.82%	-34.09%	0.00%	-27.14%	-13.36%	-11.07%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-10	-9.17	-9.54	-8.76	-7.60	-7.47	-5.83	-6.46	-6.04
NOPAT Margin	-88.55%	-65.22%	-52.42%	-45.83%	-39.45%	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%
Net Nonoperating Expense Percent (NNEP)	-5.82%	-5.73%	-3.82%	-4.05%	-3.66%	-1.68%	-1.38%	-0.14%	0.07%	0.06%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.89%	-	-	-	-4.70%	-	-	-	-2.06%
Cost of Revenue to Revenue	57.54%	53.86%	40.73%	42.26%	38.15%	38.23%	29.91%	30.49%	28.58%	28.41%
SG&A Expenses to Revenue	118.32%	97.78%	92.94%	87.65%	86.23%	74.05%	79.03%	69.63%	72.52%	70.15%
R&D to Revenue	50.64%	41.53%	41.21%	35.56%	31.99%	25.69%	27.21%	23.77%	25.03%	22.90%
Operating Expenses to Revenue	168.96%	139.32%	134.16%	123.21%	118.22%	99.74%	106.24%	93.40%	97.54%	93.04%
Earnings before Interest and Taxes (EBIT)	-16	-15	-13	-14	-13	-11	-11	-8.33	-9.23	-8.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-15	-13	-14	-13	-11	-11	-9.59	-11	-11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.46	3.91	3.89	6.23	6.16	9.02	11.64	8.13	7.07	4.93
Price to Tangible Book Value (P/TBV)	3.46	3.91	3.89	6.23	6.16	9.02	11.64	8.13	7.07	4.93
Price to Revenue (P/Rev)	8.02	7.17	9.79	14.61	12.98	16.23	18.87	19.43	15.29	9.90
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.89	10.63	13.41	26.99	27.84	38.30	45.17	38.32	34.21	20.91
Enterprise Value to Revenue (EV/Rev)	6.34	5.89	7.86	12.73	11.28	14.82	17.64	17.50	13.52	8.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.45	0.48	0.29	0.14	0.01	0.01	0.01	0.04	0.04	0.04
Long-Term Debt to Equity	0.45	0.48	0.29	0.14	0.01	0.01	0.01	0.04	0.04	0.04
Financial Leverage	-0.79	-0.78	-0.79	-0.79	-0.78	-0.75	-0.76	-0.81	-0.81	-0.80
Leverage Ratio	1.46	1.50	1.42	1.35	1.31	1.33	1.25	1.16	1.12	1.13
Compound Leverage Factor	1.53	1.56	1.43	1.37	1.30	1.13	1.06	0.84	0.77	0.78
Debt to Total Capital	31.13%	32.37%	22.73%	12.04%	0.88%	0.79%	0.55%	3.73%	3.67%	3.91%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	31.13%	32.37%	22.73%	12.04%	0.88%	0.79%	0.55%	3.73%	3.67%	3.91%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	68.87%	67.63%	77.27%	87.96%	99.12%	99.21%	99.45%	96.27%	96.33%	96.09%
Debt to EBITDA	-0.62	-0.72	-0.74	-0.38	-0.03	-0.02	-0.02	-0.24	-0.25	-0.27
Net Debt to EBITDA	1.00	1.04	1.92	2.19	2.37	2.44	2.51	4.95	5.29	5.35
Long-Term Debt to EBITDA	-0.62	-0.72	-0.74	-0.38	-0.03	-0.02	-0.02	-0.24	-0.25	-0.27
Debt to NOPAT	-0.98	-0.97	-1.02	-0.53	-0.04	-0.04	-0.03	-0.36	-0.39	-0.44
Net Debt to NOPAT	1.58	1.42	2.66	3.11	3.44	3.59	3.73	7.51	8.28	8.75
Long-Term Debt to NOPAT	-0.98	-0.97	-1.02	-0.53	-0.04	-0.04	-0.03	-0.36	-0.39	-0.44
Altman Z-Score	-0.56	-0.66	3.11	12.43	25.95	35.80	56.24	42.85	34.00	20.90
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.50	7.81	12.62	10.89	8.87	8.06	9.20	14.33	12.67	11.36
Quick Ratio	7.44	6.77	11.20	9.68	7.77	7.05	8.02	13.20	11.60	10.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-15	-20	-16	-13	-15	-13	-27	-26	-27
Operating Cash Flow to CapEx	-2,618.62%	-3,827.07%	-2,378.05%	-413.93%	-1,222.36%	-521.75%	-473.26%	-264.41%	58.93%	-502.95%
Free Cash Flow to Firm to Interest Expense	-8.76	-10.55	-13.49	-8.31	-8.11	-4,978.57	-2,205.83	-4,471.18	-5,228.64	-6,759.83
Operating Cash Flow to Interest Expense	-11.69	-9.55	-11.79	-3.91	-4.88	-2,767.00	-1,551.50	-671.17	130.00	-1,065.00
Operating Cash Flow Less CapEx to Interest Expense	-12.14	-9.80	-12.28	-4.85	-5.27	-3,297.33	-1,879.33	-925.00	-90.60	-1,276.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.29	0.30	0.37	0.45	0.54	0.52	0.46	0.52	0.56
Accounts Receivable Turnover	6.18	6.20	6.29	6.64	6.31	5.70	5.91	5.90	6.32	5.56
Inventory Turnover	1.98	2.42	2.23	2.15	1.93	2.19	2.01	2.08	1.99	2.08
Fixed Asset Turnover	3.66	4.59	5.56	6.20	7.34	8.49	9.44	10.03	11.40	12.03
Accounts Payable Turnover	8.38	12.92	9.40	8.76	7.99	10.94	8.44	8.55	9.32	9.75
Days Sales Outstanding (DSO)	59.05	58.91	58.01	54.96	57.82	64.00	61.77	61.82	57.77	65.64
Days Inventory Outstanding (DIO)	184.05	150.78	163.63	169.46	189.18	166.71	181.27	175.60	183.01	175.58
Days Payable Outstanding (DPO)	43.55	28.25	38.84	41.69	45.70	33.38	43.26	42.70	39.16	37.44
Cash Conversion Cycle (CCC)	199.55	181.44	182.80	182.73	201.29	197.33	199.78	194.72	201.63	203.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	27	27	34	32	31	34	39	53	51	55
Invested Capital Turnover	1.57	1.98	2.05	2.36	2.66	2.89	2.76	2.74	3.14	3.11
Increase / (Decrease) in Invested Capital	0.21	4.81	11	6.51	4.52	7.34	5.77	21	20	21
Enterprise Value (EV)	262	288	452	853	864	1,320	1,783	2,015	1,735	1,160
Market Capitalization	332	351	563	979	994	1,446	1,908	2,238	1,962	1,386
Book Value per Share	$3.47	$3.24	$4.29	$4.63	$4.53	$4.47	$4.43	$7.40	$6.99	$6.98
Tangible Book Value per Share	$3.47	$3.24	$4.29	$4.63	$4.53	$4.47	$4.43	$7.40	$6.99	$6.98
Total Capital	139	133	188	179	163	162	165	286	288	293
Total Debt	43	43	43	22	1.43	1.29	0.91	11	11	11
Total Long-Term Debt	43	43	43	22	1.43	1.29	0.91	11	11	11
Net Debt	-69	-63	-111	-126	-130	-126	-124	-223	-227	-226
Capital Expenditures (CapEx)	0.58	0.36	0.75	1.82	0.65	1.59	1.97	1.52	1.10	0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.96	12	19	17	17	20	25	28	27	31
Debt-free Net Working Capital (DFNWC)	123	117	173	164	149	148	150	262	264	268
Net Working Capital (NWC)	123	117	173	164	149	148	150	262	264	268
Net Nonoperating Expense (NNE)	5.65	5.12	4.04	4.27	3.66	1.58	1.63	0.25	-0.12	-0.10
Net Nonoperating Obligations (NNO)	-69	-63	-111	-126	-130	-126	-124	-223	-227	-226
Total Depreciation and Amortization (D&A)	0.73	0.32	-0.12	-0.52	-0.46	-0.49	-0.37	-1.25	-1.63	-2.11
Debt-free, Cash-free Net Working Capital to Revenue	24.09%	23.50%	32.75%	25.05%	22.36%	22.81%	24.61%	24.59%	21.05%	21.96%
Debt-free Net Working Capital to Revenue	297.01%	239.40%	300.23%	244.59%	194.56%	165.59%	148.60%	227.13%	205.88%	191.49%
Net Working Capital to Revenue	297.01%	239.40%	300.23%	244.59%	194.56%	165.59%	148.60%	227.13%	205.88%	191.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.61)	($0.55)	($0.42)	($0.40)	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)
Adjusted Weighted Average Basic Shares Outstanding	27.67M	27.66M	31.64M	34.50M	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M
Adjusted Diluted Earnings per Share	($0.61)	($0.55)	($0.42)	($0.40)	($0.35)	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)
Adjusted Weighted Average Diluted Shares Outstanding	27.67M	27.66M	31.64M	34.50M	35.66M	34.46M	36.84M	38.46M	39.79M	38.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.72M	33.78M	33.98M	35.64M	35.86M	36.99M	37.20M	39.68M	40.30M	40.49M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-10	-9.17	-9.54	-8.76	-7.60	-7.47	-5.83	-6.46	-6.04
Normalized NOPAT Margin	-88.55%	-65.22%	-52.42%	-45.83%	-39.45%	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%
Pre Tax Income Margin	-133.32%	-97.00%	-75.54%	-66.21%	-55.87%	-32.17%	-30.80%	-17.38%	-17.91%	-14.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-12.28	-10.33	-8.69	-7.06	-7.64	-3,617.00	-1,778.33	-1,388.83	-1,845.20	-2,157.25
NOPAT to Interest Expense	-8.60	-7.23	-6.08	-4.94	-5.35	-2,531.90	-1,244.83	-972.18	-1,291.64	-1,510.08
EBIT Less CapEx to Interest Expense	-12.73	-10.58	-9.19	-8.00	-8.04	-4,147.33	-2,106.17	-1,642.67	-2,065.80	-2,369.00
NOPAT Less CapEx to Interest Expense	-9.05	-7.48	-6.58	-5.89	-5.75	-3,062.23	-1,572.67	-1,226.02	-1,512.24	-1,721.83
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.08%	-0.88%	-1.31%	-2.00%	-1.71%	-1.28%	-0.88%	-1.08%	-2.42%	-2.80%

Financials Breakdown Chart

Key Financial Trends

RxSight (NASDAQ: RXST) has shown top-line growth in 2024 with strong gross margins, but continues to incur quarterly losses and some cash burn. Below is a concise, HTML-formatted snapshot of trends drawn from the last four years of quarterly statements provided.

Revenue growth in Q4 2024 vs Q3 2024: Operating revenue increased from 35.31 million to 40.21 million, roughly a 14% sequential rise, indicating improving top-line momentum.
Gross margin remains robust and relatively stable: 2024 quarters show gross margins around 70% (Q4 2024 around 71.6%, Q3 2024 ~71.3%, Q2 2024 ~69.6%, Q1 2024 ~70.1%), suggesting the core product margin stays favorable even as costs evolve.
Strong liquidity on the balance sheet: In 2024 Q3, total current assets (~$286.8M) far exceed total current liabilities (~$22.6M), implying a very high current ratio and ample near-term liquidity.
Cash flow from operations improved in Q3 2024: Net cash from continuing operating activities was about $0.65M (positive), a notable improvement after negative cash flow in early 2024, though it moderated again in Q4.
Access to capital via equity issuance: RxSight raised cash through common equity issuances in 2024 (e.g., roughly $3.84M in Q3 2024 and $2.99M in Q4 2024), supporting liquidity as it funds ongoing investments and losses.
No long-term debt on the balance sheet; long-term debt is zero with capital lease obligations around $10.6M, indicating relatively low leverage at the snapshot level. This remains neutral pending future financing decisions.
Equity base remains substantial despite losses: Retained earnings are negative (e.g., about -$616.2M in 2024 Q3), but total equity sits at roughly $277M, reflecting ongoing capital raises and accounting structure. This is a mixed signal and considered neutral in the current context.
Net income remains negative: 2024 Q4 net income of -$5.94M; Q3 -$6.34M; Q2 -$6.08M; Q1 -$9.10M, underscoring persistent profitability challenges.
Operating expenses outpace revenue: In Q4 2024, operating expenses (SG&A plus R&D) were $37.42M on $40.21M revenue, producing an operating loss and indicating ongoing cost discipline is needed.
Ongoing cash burn from operations in most quarters: Net cash from continuing operating activities was negative in Q1 2024, Q2 2024, and Q4 2024, with only a partial positive in Q3 2024, highlighting continued cash burn absent substantial financing or investing inflows.

05/05/26 06:07 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About RxSight's Financials

When does RxSight's financial year end?

According to the most recent income statement we have on file, RxSight's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has RxSight's net income changed over the last 2 years?

RxSight's net income appears to be on a downward trend, with a most recent value of -$27.46 million in 2024, falling from -$66.76 million in 2022. The previous period was -$48.61 million in 2023. See where experts think RxSight is headed by visiting RxSight's forecast page.

What is RxSight's operating income?

RxSight's total operating income in 2024 was -$36.86 million, based on the following breakdown:

Total Gross Profit: $98.94 million
Total Operating Expenses: $135.80 million

How has RxSight's revenue changed over the last 2 years?

Over the last 2 years, RxSight's total revenue changed from $49.01 million in 2022 to $139.93 million in 2024, a change of 185.5%.

How much debt does RxSight have?

RxSight's total liabilities were at $37.33 million at the end of 2024, a 68.2% increase from 2023, and a 38.1% decrease since 2022.

How much cash does RxSight have?

In the past 2 years, RxSight's cash and equivalents has ranged from $9.69 million in 2023 to $16.71 million in 2024, and is currently $16.71 million as of their latest financial filing in 2024.

How has RxSight's book value per share changed over the last 2 years?

Over the last 2 years, RxSight's book value per share changed from 3.24 in 2022 to 6.98 in 2024, a change of 115.2%.

Related Companies

Financial statements for NASDAQ:RXST last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About RxSight's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Financials

Annual Income Statements for RxSight

Quarterly Income Statements for RxSight

Annual Cash Flow Statements for RxSight

Quarterly Cash Flow Statements for RxSight

Annual Balance Sheets for RxSight

Quarterly Balance Sheets for RxSight

Annual Metrics And Ratios for RxSight

Quarterly Metrics And Ratios for RxSight

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About RxSight's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools